Background Up to half of patients with infective endocarditis (IE) require cardiac surgery. Although anaemia is common, its precise prevalence, transfusion practices and impact on outcomes in ...
Cyprus: Vassiliko Cement has appointed George Savva as its general manager with effect from 1 August 2019. In addition, Antonios Antoniou, the executive chairman of the company, will retain his ...
Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...
IFS for OCD, which is compatible with standard exposure and response prevention (ERP), brings comfort and respect to the ...
This discussion has been edited for length and clarity. Three clinicians explore the headline-making evidence from the monarchE and NATALEE trials presented at the 2025 ESMO Congress. Laura A. Huppert ...
Background The National Heart Failure Audit gathers data on patients coded at discharge (or death) as having heart failure as ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for ...
On Day 8 of the trial, France, second from left, explained his reasoning for resisting permanent charters to teams. Grant Baldwin / Getty Images CHARLOTTE, N.C. — NASCAR chairman and CEO Jim France ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback